Market Cap 6.16M
Revenue (ttm) 10,000.00
Net Income (ttm) -18.46M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -184,600.00%
Debt to Equity Ratio 3.89
Volume 9,262,100
Avg Vol 73,195,156
Day's Range N/A - N/A
Shares Out 29.43M
Stochastic %K 36%
Beta 7.47
Analysts Strong Buy
Price Target N/A

Company Profile

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research, development, manufacture, sale, and distribution of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that has completed Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 61 4 0984 0786
Address:
8 Century Circuit, Suite 105 Norwest, Sydney, Australia
malibu_rum67
malibu_rum67 Jul. 7 at 1:56 AM
0 · Reply
Soly96
Soly96 Jul. 7 at 1:55 AM
$IXHL On 5/14 we had over 1.5 billion shares traded . Can we see it again in July?
0 · Reply
StrawberryRips
StrawberryRips Jul. 7 at 1:49 AM
$IXHL Phase 2 data any day now in July. Strong positive outlook, previously known to run 100’s of %. OSA is a ~$10 Billion market, IXHL at only ~$20. Watching this week, or the next couple, for a big move to the upside on positive data. .20/.22 nice entry. Holding 77k shares at .199 personally. $SPY $IWM
0 · Reply
D1357912
D1357912 Jul. 7 at 1:23 AM
$IXHL up over 3% overnight trading
0 · Reply
Soly96
Soly96 Jul. 7 at 1:22 AM
0 · Reply
krispen
krispen Jul. 7 at 1:15 AM
$IXHL Two thoughts: 1) Marijuana has been used for sleep related disorders for years prior to cannabinoid product development by people who have been self-medicating to improve their sleep patterns, so it is a small step to see how a properly synthesized cannabinoid product can alleviate one of the leading sleep deficit causes in apnea. 2) Beyond the fact that July has already been stated the timeframe for next PR on IXHL’s OSA product status, it is logical for the release to try and pre-empt another potential tariff increase and it’s market effects at the end of July in anticipation of August impacts as announced by the WH. This may further prompt a sooner than later announcement to catalyze the market by mid-July imho. Just my $0.02 Very BULLISH for a BLAST-OFF any day now! 🔥🔥🔥🚀🚀🚀
1 · Reply
Olivia_Strickland
Olivia_Strickland Jul. 7 at 1:08 AM
$IXHL what happened on 4/29 for the sharp dump then on 5/14 the sharp pump to .70? trying to see if this is something I want to scalp tomorrow.
1 · Reply
WangSLO
WangSLO Jul. 7 at 12:43 AM
$IXHL if this is a.p&d, can we at least send it to 35 before dumping @Santa_Claus_Trades
1 · Reply
findom
findom Jul. 7 at 12:37 AM
$IXHL Let’s keep it real and grounded … If IHL‑42X shows strong Phase 2 efficacy and safety, IXHL’s fair market cap could plausibly reach: 🎯 $500 million to $1.5 billion, 📈 compared to ~$50 million today — a potential 10x+ upside, contingent on continued progress. So, at around $500 million, it would be 10x today’s MC, or $2.00 pps (Low). At $1 Billion, $4.00 pps (Med) and $1.5 Billion, $6.00 pps. (High) The above does not reflect any momentary overreaction to the news and FOMO effect.
1 · Reply
WangSLO
WangSLO Jul. 7 at 12:35 AM
$IXHL i think this is the first time i fully think @Santa_Claus_Trades is actually holding
0 · Reply
Latest News on IXHL
Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL)

Oct 2, 2024, 4:50 PM EDT - 9 months ago

Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL)


Clarion Clinics Open for Psychedelic-Assisted Treatments

Feb 1, 2024, 7:30 AM EST - 1 year ago

Clarion Clinics Open for Psychedelic-Assisted Treatments


malibu_rum67
malibu_rum67 Jul. 7 at 1:56 AM
0 · Reply
Soly96
Soly96 Jul. 7 at 1:55 AM
$IXHL On 5/14 we had over 1.5 billion shares traded . Can we see it again in July?
0 · Reply
StrawberryRips
StrawberryRips Jul. 7 at 1:49 AM
$IXHL Phase 2 data any day now in July. Strong positive outlook, previously known to run 100’s of %. OSA is a ~$10 Billion market, IXHL at only ~$20. Watching this week, or the next couple, for a big move to the upside on positive data. .20/.22 nice entry. Holding 77k shares at .199 personally. $SPY $IWM
0 · Reply
D1357912
D1357912 Jul. 7 at 1:23 AM
$IXHL up over 3% overnight trading
0 · Reply
Soly96
Soly96 Jul. 7 at 1:22 AM
0 · Reply
krispen
krispen Jul. 7 at 1:15 AM
$IXHL Two thoughts: 1) Marijuana has been used for sleep related disorders for years prior to cannabinoid product development by people who have been self-medicating to improve their sleep patterns, so it is a small step to see how a properly synthesized cannabinoid product can alleviate one of the leading sleep deficit causes in apnea. 2) Beyond the fact that July has already been stated the timeframe for next PR on IXHL’s OSA product status, it is logical for the release to try and pre-empt another potential tariff increase and it’s market effects at the end of July in anticipation of August impacts as announced by the WH. This may further prompt a sooner than later announcement to catalyze the market by mid-July imho. Just my $0.02 Very BULLISH for a BLAST-OFF any day now! 🔥🔥🔥🚀🚀🚀
1 · Reply
Olivia_Strickland
Olivia_Strickland Jul. 7 at 1:08 AM
$IXHL what happened on 4/29 for the sharp dump then on 5/14 the sharp pump to .70? trying to see if this is something I want to scalp tomorrow.
1 · Reply
WangSLO
WangSLO Jul. 7 at 12:43 AM
$IXHL if this is a.p&d, can we at least send it to 35 before dumping @Santa_Claus_Trades
1 · Reply
findom
findom Jul. 7 at 12:37 AM
$IXHL Let’s keep it real and grounded … If IHL‑42X shows strong Phase 2 efficacy and safety, IXHL’s fair market cap could plausibly reach: 🎯 $500 million to $1.5 billion, 📈 compared to ~$50 million today — a potential 10x+ upside, contingent on continued progress. So, at around $500 million, it would be 10x today’s MC, or $2.00 pps (Low). At $1 Billion, $4.00 pps (Med) and $1.5 Billion, $6.00 pps. (High) The above does not reflect any momentary overreaction to the news and FOMO effect.
1 · Reply
WangSLO
WangSLO Jul. 7 at 12:35 AM
$IXHL i think this is the first time i fully think @Santa_Claus_Trades is actually holding
0 · Reply
Xvool
Xvool Jul. 7 at 12:31 AM
$IXHL Top-line results expected July 2025 as development of first-in-class OSA drug advances ! 🚨 Phase 2 top line results this month ! https://www.globenewswire.com/news-release/2025/06/18/3101356/0/en/Incannex-achieves-key-milestone-with-database-lock-for-RePOSA-Phase-2-trial-of-IHL-42X.html
0 · Reply
malibu_rum67
malibu_rum67 Jul. 7 at 12:29 AM
0 · Reply
malibu_rum67
malibu_rum67 Jul. 7 at 12:28 AM
$IXHL … I Am Holding A HIGH VALUE ASSET!!! I Feel Rich 🤑 🤭
0 · Reply
malibu_rum67
malibu_rum67 Jul. 7 at 12:25 AM
$IXHL …. Super Bullish 🐂 💪💪💪
0 · Reply
LetsGoBflo
LetsGoBflo Jul. 7 at 12:11 AM
0 · Reply
Akicker87
Akicker87 Jul. 7 at 12:06 AM
$IXHL .2170
0 · Reply
JRP07
JRP07 Jul. 6 at 11:57 PM
$IXHL Futures are up. Tomorrow might be a perfect day to release the News!
0 · Reply
Picaxle10
Picaxle10 Jul. 6 at 11:02 PM
$IXHL phase 2 data anyday with phase 3 FDA authorization in place 🚀🚀 Ixhl Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance With the FDA authorization in place, Incannex will initiate Phase 3 immediately following the completion of Phase 2, leveraging a shared protocol and U.S. based infrastructure to maximize efficiency and speed. “The progression of RePOSA into Phase 3 represents a major milestone for Incannex and our shareholders,” said Joel Latham, President and CEO of Incannex. “IHL-42X is a high-value asset targeting one of the most prevalent and under-treated conditions globally, OSA. With FDA clearance, a streamlined study design, and the drug product already manufactured, we are uniquely positioned to execute efficiently and deliver meaningful value. IHL-42X has the potential to become the first FDA-approved oral therapy for obstructive sleep apnea, and we believe it could transform the treatment paradigm for millions of patients across the globe.”
0 · Reply
malibu_rum67
malibu_rum67 Jul. 6 at 10:42 PM
0 · Reply
Manika2002
Manika2002 Jul. 6 at 10:33 PM
$IXHL @Santa_Claus_Trades i think you are really IN 👍
0 · Reply
Santa_Claus_Trades
Santa_Claus_Trades Jul. 6 at 10:14 PM
$IXHL Reasons why we would be a good canidate for a future buyout. Cleaned up Capital Structure: Incannex has actively worked to reduce potential future dilution by canceling Series A Warrants, which can make the company more attractive to potential acquirers who prefer a simpler and cleaner capital structure. Upcoming Catalysts: The impending release of Phase 2 data for IHL-42X, a treatment for obstructive sleep apnea, could be a significant event. Positive results could substantially increase the company's value and attract potential buyers interested in this specific therapeutic area. Focus on a First-in-Class Treatment: IHL-42X is highlighted as a potential first-in-class oral therapy for obstructive sleep apnea, a condition with significant unmet medical needs. This could make it a particularly attractive acquisition target for larger pharmaceutical companies looking to enter or expand in this market.
1 · Reply
Santa_Claus_Trades
Santa_Claus_Trades Jul. 6 at 10:03 PM
$IXHL How high could our baby girl go, just on Phase 2 success alone...JMO Positive Market Response: A successful Phase 2 trial for IHL-42X in treating obstructive sleep apnea (OSA) would likely be met with positive market sentiment, potentially leading to a significant increase in the stock price. Addressing an Unmet Need: IHL-42X is designed as a first-in-class oral treatment for OSA, potentially addressing a large market with limited current options. This could drive substantial value for the company and investors. Analyst Estimates: Some analyst forecasts, like Stonegate Capital Partners, have suggested significant upside potential for IXHL, potentially over 200% premium to the current market price, based on successful clinical progression and market opportunities. Eliminating Dilution: Incannex has taken steps to reduce potential future dilution by canceling warrants, which could increase the value per share if IHL-42X succeeds.
0 · Reply